CMS certification 063301
Children's Hospital Colorado
13123 E 16th Ave, Aurora, CO 80045
This page brings together federal quality data for this hospital: its CMS star rating, patient survey results, emergency department times, and death, complication, infection and readmission rates, each compared with the national rate. Everything here comes from CMS and NPPES, the federal sources themselves - not from us.
What patients said
Answers from patients who stayed here, collected by CMS in the national HCAHPS survey: Oct 2024 – Sep 2025.
Not reported for this hospital
CMS had too few cases here to publish results for deaths, complications, infections caught in the hospital, readmissions and return visits. That is common at small, rural and specialty hospitals, and says nothing either way about quality.
Clinicians registered at this address
2,539 clinicians give this hospital's street address as their practice location in NPPES, the federal provider registry, plus 162 residents and trainees. The same address can take in offices and clinics in the building, and a listing does not prove admitting privileges or current employment.
| Specialty | Clinicians |
|---|---|
| Pediatrics | 417 |
| Pediatric Emergency Medicine | 163 |
| Medical | 134 |
| Clinical | 133 |
| Clinical Child & Adolescent | 91 |
| Hospitalist | 89 |
| Pediatric Hematology-Oncology | 70 |
| Pediatric Anesthesiology | 65 |
| Acute Care | 57 |
| Pediatric Critical Care Medicine | 55 |
| Neonatal-Perinatal Medicine | 53 |
| Pediatric Cardiology | 51 |
First 12 alphabetically
Money from drug and device companies
Drug and device makers have to report what they pay teaching hospitals to CMS's Open Payments program. At many teaching hospitals most of it is research funding, or royalties for inventions the hospital licensed to a company. A payment on its own does not show a conflict of interest.
- 2019 $3.8M
- 2020 $3.7M
- 2021 $9.4M
- 2022 $8.8M
- 2023 $6.3M
- 2024 $8.6M
- 2025 $8.2M
What the 2025 general payments were for
| Type of payment | Amount | Payments |
|---|---|---|
| Consulting fees | $222,306 | 5 |
| Space rental and facility fees | $61,050 | 25 |
| Medical devices and supplies on long-term loan | $52,874 | 18 |
| Grants | $27,000 | 2 |
| Speaking, teaching and other services | $22,970 | 19 |
| Debt forgiveness | $16,942 | 15 |
| Charitable contributions | $15,000 | 2 |
| Gifts | $750 | 1 |
| Education | $500 | 1 |
Largest paying companies, 2025
| Company | Amount | Payments |
|---|---|---|
| Novartis Pharmaceuticals Corporation | $673,773 | 9 |
| Merck Sharp & Dohme LLC | $480,301 | 15 |
| Ultragenyx Pharmaceutical Inc. | $465,948 | 38 |
| Ionis Pharmaceuticals, Inc. | $442,218 | 9 |
| Abbvie INC. | $420,696 | 57 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $370,245 | 25 |
| Vertex Pharmaceuticals Incorporated | $366,890 | 4 |
| Rhythm Pharmaceuticals, Inc. | $358,426 | 125 |
Largest research studies funded here, 2025
| Study | Amount |
|---|---|
| A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Idiopa… Novartis Pharmaceuticals Corporation | $597,712 |
| An open-label trial of the long-term safety and tolerability of nintedanib per os, on top of standard of care, over at least 2 years, in children and… Boehringer Ingelheim Pharmaceuticals, Inc. | $348,245 |
| New InsiGHts Ascendis Pharma Endocrinology Inc · NCT05690386 | $243,464 |
| GTX-102-CL301 Ultragenyx Pharmaceutical Inc. · NCT06617429 | $216,666 |
| A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity Rhythm Pharmaceuticals, Inc. | $212,221 |
| ION582CS1 Ionis Pharmaceuticals, Inc. | $210,885 |
| A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esoph… AstraZeneca Pharmaceuticals LP | $201,616 |
| ACP-101-302 ACADIA Pharmaceuticals Inc · NCT06173531 | $184,702 |
Amounts are as the paying companies reported them to CMS; Open Payments data retrieved 13 Sep 2026. Full record on CMS Open Payments.
How to read this page
- Everything here is published by CMS on Care Compare. We arrange it and explain it; the star ratings and the better / worse verdicts are CMS's, not ours.
- “No different” is the most common result on most measures at most hospitals. CMS only calls a result better or worse when the difference from the national rate is statistically clear.
- Death, complication and readmission rates are adjusted by CMS for how sick patients were, so hospitals that treat sicker patients can be compared fairly.
- Infection results are ratios: 1.0 means as many infections as CMS predicted for a hospital like this one, below 1.0 is fewer.
- These are hospital-wide results. They do not rate an individual doctor, nurse or department, and they are not medical advice.
CMS Care Compare data retrieved 4 Oct 2026, refreshed weekly. Where this data comes from and how we handle it · Report an error
Common questions about Children's Hospital Colorado
Does Children's Hospital Colorado have an emergency room?
Yes. CMS lists emergency services at Children's Hospital Colorado.
Does Children's Hospital Colorado receive money from drug and device companies?
Drug and device makers reported $8.2M in payments to Children's Hospital Colorado for 2025, most of it research funding, under the federal Open Payments program. A payment on its own does not show a conflict of interest.